Skip to main content
SpringerLink
Log in

Extemporaneously Used Drug Formulations for Ocular Emergencies

  • Chapter
  • First Online:
Pharmacology of Ocular Therapeutics

Abstract

Extemporaneously compounded formulations are often used in regular ophthalmic practice. Dispensing drug for ophthalmic purposes require adequate skills and experience to customize formulations for individuals. Compounding ophthalmic formulations is a precise task requiring strict control over pH, osmolarity, sterility and knowledge about their stability. This chapter covers benefits of extemporaneously compounded formulations, regulatory requirements of compounding pharmacy, components of ophthalmic formulations, requirements for active/auxiliary ingredients, sterilization procedures, packaging, cost effectiveness, related risk factors and stability of compounded formulations etc.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Al-Badriyeh D, Li J, Stewart K, Kong DC, Leung L, Davies GE, Fullinfaw R. Stability of extemporaneously prepared voriconazole ophthalmic solution. Am J Health Syst Pharm. 2009;66(16):1478–83. doi:10.2146/ajhp080110.

    Article  PubMed  CAS  Google Scholar 

  • Aldricha DS, Bacha CM, Brown W, Chambers W, Fleitmana J, Hunt D, Marquesb MRC, Millee Y, Mitra AK, Platzer SM, Tice T, Tin GW. Ophthalmic preparations. 2013;39(5). (P)\\uspnetapp2\share\SHARE\USPNF\PRINTQ\pager\xmlIn\NEP_20130828110441_S200824.xml. Aug 28 2013 11:04:44.

    Google Scholar 

  • All drug products intended for ophthalmic use must be sterile. 21 CFR 200.50. USFDA, 2014.

    Google Scholar 

  • AmorosReboredo P, BastidaFernandez C, GuerreroMolina L, SoyMuner D, LopezCabezas C. Stability of frozen 1 % voriconazole ophthalmic solution. Am J Health Syst Pharm. 2015;72(6):479–82. doi:10.2146/ajhp140127.

    Article  CAS  Google Scholar 

  • Anaizi NH, Swenson CF, Dentinger PJ. Stability of acetylcysteine in an extemporaneously compounded ophthalmic solution. Am J Health Syst Pharm. 1997;54(5):549–53.

    PubMed  CAS  Google Scholar 

  • Anderson Jr ER. Proper dose, preparation, and storage of botulinum neurotoxin serotype A. Am J Health Syst Pharm. 2004;61(22 Suppl 6):S24–9.

    PubMed  CAS  Google Scholar 

  • Aquilina A. The extemporaneous compounding of paediatric medicines at Mater Dei Hospital. J Malta Coll Pharm Pract. 2013;19:28–30.

    Google Scholar 

  • Arici MK, Sumer Z, Guler C, Elibol O, Saygi G, Cetinkaya S. In vitro potency and stability of fortified ophthalmic antibiotics. Aust N Z J Ophthalmol. 1999;27(6):426–30.

    Article  PubMed  CAS  Google Scholar 

  • Aseptic Processing of Health Care Products. 1 – General requirements. Geneva: IS0 13408–1, International Standards Organization; 1997.

    Google Scholar 

  • Baum JL. Chapter 26: Antibiotic use in ophthalmology. In: Duane’s Ophthalmology. Ed: William Tasman. Vol 4, Lippincott Williams & Wilkins, Hagerstown, MD. 2006. Available at: http://www.oculist.net/downaton502/prof/ebook/duanes/pages/v4/v4c026.html

  • Benavides JO, Satchell ER, Frantz KA. Efficacy of a mydriatic spray in the pediatric population. Optom Vis Sci. 1997;74(3):160–3.

    Article  PubMed  CAS  Google Scholar 

  • Biju J. Intravitreal injections. Kerala J Ophthalmol. 2007;XIX(1):46–57.

    Google Scholar 

  • Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol. 2011;5:191–6. [PMCID: PMC3120237] [PubMed: 21586838].

    Article  Google Scholar 

  • Blondeel S, Pelloquin A, Pointereau-Bellanger A, Thuillier A, Fernandez C. Effect of freezing on stability of a fortified 5 mg/mL ticarcillin ophthalmic solution. Can J Hosp Pharm. 2005;58(2):65–70.

    Google Scholar 

  • Bowe BE, Snyder JW, Eiferman RA. An in vitro study of the potency and stability of fortified ophthalmic antibiotic preparations. Am J Ophthalmol. 1991;111(6):686–9.

    Article  PubMed  CAS  Google Scholar 

  • Buitrago E, Lagomarsino E, Mato G, Schaiquevich P. Stability of melphalan solution for intravitreal injection for retinoblastoma. JAMA Ophthalmol. 2014;132(11):1372–3. doi:10.1001/jamaophthalmol.2014.2324.

    Article  PubMed  Google Scholar 

  • Buurma H, de Smet PAGM, van den Hoff OP, Sysling H, Storimans M, Egberts ACG. Frequency, nature and determinants of pharmacy compounded medicines in Dutch community pharmacies. Pharm World Sci. 2003;25(6):280–7.

    Article  PubMed  Google Scholar 

  • Cabaleiro J. Obtaining accreditation by the Pharmacy Compounding Accreditation Board, part 2: developing essential standard operating procedures. Int J Pharm Compd. 2007;11(5):397–9.

    PubMed  Google Scholar 

  • Cabaleiro J. Obtaining accreditation by the Pharmacy Compounding Accreditation Board, part 4: tips for “last minute” preparations. Int J Pharm Compd. 2008;12(5):432–3.

    Google Scholar 

  • Centers for Disease Control and Prevention (CDC). Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy – United States, 2012. MMWR Morb Mortal Wkly Rep. 2012a;61:839–42.

    Google Scholar 

  • Centers for Disease Control and Prevention (CDC). Notes from the field: multistate outbreak of post-procedural fungal endophthalmitis associated with a single compounding pharmacy-United States, March-April 2012. MMWR Morb Mortal Wkly Rep. 2012b;61:310–1.

    Google Scholar 

  • Charlton JF, Dalla KP, Kniska A. Storage of extemporaneously prepared ophthalmic antimicrobial solutions. Am J Health Syst Pharm. 1998;55(5):463–6.

    PubMed  CAS  Google Scholar 

  • Chast F, Lemare F, Legeais JM, Batista R, Bardin C, Renard G. Cyclosporine 2 % eye drops preparation. J Fr Ophtalmol. 2004;27(6 Pt 1):567–76.

    Article  PubMed  CAS  Google Scholar 

  • Chen YH, Wu PC, Shiea J, Lo LH, Wu YC, Kuo HK. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J Ocul Pharmacol Ther. 2009;25(1):65–9. doi:10.1089/jop.2008.0043.

    Article  PubMed  CAS  Google Scholar 

  • Compounding quality act (Drug Quality and Security Act of 2013). USFDA 2015. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm2007064.htm. Accessed on 28 Feb 2015.

  • CSHP. Guidelines for preparation of sterile products in pharmacies. 1996.

    Google Scholar 

  • Daniels R. Compounding of ophthalmic drugs in the pharmacy. Special care must be taken. Pharm Unserer Zeit. 2010;39(4):306–11. doi:10.1002/pauz.201000377.

    Article  PubMed  Google Scholar 

  • Davis AR, Ali QH, Aclimandos WA, Hunter PA. Topical steroid use in the treatment of ocular alkali burns. Br J Ophthalmol. 1997;81:732–4. doi:10.1136/bjo.81.9.732.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • De Rojas V. Infectious keratitis in 18,651 laser surface ablation procedures. J Cataract Refract Surg. 2011;37(10):1822–31.

    Article  PubMed  Google Scholar 

  • Division of Transplant and Ophthalmology Products Office of Antimicrobial Products of New Drugs. Center for Drug Evaluation and Research FDA; Dermatologic and Ophthalmic Drugs Advisory Committe. Silver Spring, MD. February 27, 2012. Accessed 21 Apr 2015.

    Google Scholar 

  • Dreno C, Gicquel T, Harry M, Tribut O, Aubin F, Brandhonneur N, Dollo G. Formulation and stability study of a pediatric 2 % phenylephrine hydrochloride eye drop solution. Ann Pharm Fr. 2015;73(1):31–6. doi:10.1016/j.pharma.2014.06.006. Jul 14.

    Article  PubMed  CAS  Google Scholar 

  • Euradlex. The Rules Governing Medicinal Products in the European Community, Annex 1, published by the European Commission: Brussels, 2014.

    Google Scholar 

  • Fagerstrom R. A note on the stability of ophthalmic solutions containing pilocarpine hydrochloride alone and with eserine. J Pharm Pharmacol. 2011;15(1):479–82.

    Article  Google Scholar 

  • FDA warning regarding Pseudomonas endophthalmitis and keratitis from compounded contaminated indomethacin eye drops used after cataract surgery. New York Times (cited in Schein 1992 on December 9, 1990).

    Google Scholar 

  • FDA Consumer Health Information / U.S. Food and Drug Administration: The special risks of pharmacy compounding. (Dec 2012) Available at: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM107839.pdf.

  • Fiscella RG, Le H, Lam TT, Labib S. Stability of cyclosporine 1 % in artificial tears. J Ocul Pharmacol Ther. 1996;12(1):1–4.

    Article  PubMed  CAS  Google Scholar 

  • Fischer KR, Opitz A, Böeck M, Geerling G. Stability of serum eye drops after storage of 6 months. Cornea. 2012;31(11):1313–8. doi:10.1097/ICO.0b013e3182542085.

    Article  PubMed  Google Scholar 

  • Food and Drug Administration. Guideline on Sterile Drug Products Produced by Aseptic Processing FDA, Rockville, 2004.

    Google Scholar 

  • Francoeur AM, Assalian A, Lesk MR, Morin I, Tetreault F, Calleja K, Guttman A, Rauth M, Pan SS. A comparative study of the chemical stability of various mitomycin C solutions used in glaucoma filtering surgery. J Glaucoma. 1999;8:242–6.

    Article  PubMed  CAS  Google Scholar 

  • Fuhrman Jr LC, Stroman RT. Stability of vancomycin in an extemporaneously compounded ophthalmic solution. Am J Health Syst Pharm. 1998;55(13):1386–8.

    PubMed  CAS  Google Scholar 

  • Fuhrman Jr LC, Godwin DA, Davis RA. Stability of 5fluorouracil in an extemporaneously compounded ophthalmic solution. Int J Pharm Compd. 2000;4(4):320–3.

    PubMed  CAS  Google Scholar 

  • Geyer O, et al. Microbial contamination of medications used to treat glaucoma. Br J Ophthalmol. 1995;79:376–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Giam JA, McLachlan AJ, Krass I. Characterizing specialized compounding in community pharmacies. Res Social Adm Pharm. 2012;8:240–52.

    Article  PubMed  Google Scholar 

  • Glass BD, Haywood A. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. J Pharm Pharm Sci. 2006;9(3):398–426.

    PubMed  CAS  Google Scholar 

  • Goldberg RA, Flynn Jr HW, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153:204–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Good compounding practices applicable to state-licensed pharmacies. In: Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy. Park Ridge, Ill: National Association of Boards of Pharmacy; 1993:C.1–5. 3.

    Google Scholar 

  • Government Printing Office. Drug Quality and Security Act. 2013. http://www.gpo.gov/fdsys/pkg/BILLS-113hr3204enr/pdf/BILLS-113hr3204enr.pdf. Accessed on 28 Feb 2015.

  • Hecht G. Ophthalmic preparation. In: Gennaro AR, editor. Remington: the science and practice of pharmacy. 20th ed. Easton: Mack Publishing Co; 2000. p. 821–35.

    Google Scholar 

  • Houck LK. Compounding: a well-established practice in 1938. Int J Pharm Compd. 2005;9(5):364–7.

    PubMed  Google Scholar 

  • IACP. Member Alert. 2012. Available at http://www.iacprx.org/displaycommon.cfm?an=1&subarticlenbr=277. Accessed 10 Apr 2015.

  • ICH. Stability testing of new drug substances and products Q1A (R2), 2003. http://private.ich.org/LOB/media/MEDIA419.pdf. Accessed 15 Feb 2015.

  • International Academy of Compounding Pharmacists. One size doesn’t fit all; 2014, available from: http://www.iacprx.org/displaycommon.cfm?an=1&subarticlenbr=128. Cited 25 Apr 2014.

  • ISO 14698–1. Cleanrooms and associated controlled environments–Biocontamination Control: part 1: general principles and methods. Geneva: International Organisation for Standardization; 2003.

    Google Scholar 

  • ISPE Baseline® Pharmaceutical Engineering Guide, Volume 3 - Sterile Manufacturing Facilities, International Society for Pharmaceutical Engineering (ISPE), First Edition, January 1999. Available at www.ispe.org

  • Jokl DHK, et al. Bacterial contamination of ophthalmic solutions used in an extended care facility. Br J Ophthalmol. 2007;91:1308–10.

    Article  PubMed Central  PubMed  Google Scholar 

  • Khangtragool A, Santidherakul S, Leesawat P. Stability of vancomycin 31 mg/mL in extemporaneous eye drops determined with capillary electrophoresis. Chiang Mai J Sci. 2011;38(4):533–40.

    CAS  Google Scholar 

  • Kodym A, Hapka-Zmich D, Gołab M, Gwizdala M. Stability of ceftazidime in 1 % and 5 % buffered eye drops determined with HPLC method. Acta Pol Pharm. 2011a;68(1):99–107.

    PubMed  CAS  Google Scholar 

  • Kodym A, Kaczyńska-Dyba E, Kubiak B, Kukuła H. Technology of eye drops containing metronidazole. Acta Pol Pharm. 2011b;68(1):109–14.

    PubMed  CAS  Google Scholar 

  • Kodym A, Pawłowska M, Rumiński JK, Bartosińska A, Kieliba A. Stability of cefepime in aqueous eye drops. Pharmazie. 2011c;66(1):17–23.

    PubMed  CAS  Google Scholar 

  • Kodym A, Wiśniewski A, Knioła D, Olejniczak M. Stability of cefuroxime in 1 % and 5 % buffered eye drops determined with HPLC method. Acta Pol Pharm. 2011d;68(4):555–64.

    PubMed  CAS  Google Scholar 

  • Kodym A, Bilski P, Domańska A, Hełminiak Ł, Jabłońska M, Jachymska A. Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method. Acta Pol Pharm. 2012;69(1):95–105.

    PubMed  CAS  Google Scholar 

  • Krishnan T, Sengupta S. Secondary pseudomonas infection of fungal keratitis following use of contaminated natamycin eye drops: a case series. Eye. 2009;23:477–9.

    Article  PubMed  CAS  Google Scholar 

  • Lee EW, Holtebeck AC, Harrison AR. Infection rates in outpatient eyelid surgery. Ophthal Plast Reconstr Surg. 2009;25(2):109–10.

    Article  PubMed  Google Scholar 

  • Lin S-C, et al. Formulation and stability of an extemporaneous 0.02 % chlorhexidine digluconate ophthalmic solution. J Formos Med Assoc. 2014;xx:1–8. http://dx.doi.org/10.1016/j.jfma.2014.08.003.

    Google Scholar 

  • Ling MR. Extemporaneous compounding. The end of the road? Dermatol Ther. 1998;16(2):321–7.

    CAS  Google Scholar 

  • Livingstone DJ, et al. Evaluation of an extended period of use for preserved eye drops in hospital practice. Br J Ophthalmol. 1998;82:473–5.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Llovet F. Infectious keratitis in 204, 586 LASIK procedures. Ophthalmology. 2010;117(2):232–8.

    Article  PubMed  Google Scholar 

  • Lowes R. Compounding pharmacy crackdown continues with Avastin recall. Medscape Medical News. March 19, 2013. /viewarticle/781039. Accessed 2 May 2015.

    Google Scholar 

  • Macdonald IM, Noel LP, Mintsioulis G, Clarke WN. The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis. J Pediatr Ophthalmol Strabismus. 1990;27(5):272–5.

    PubMed  CAS  Google Scholar 

  • McBride HA, Martinez DR, Trang JM, Lander RD, Helms HA. Stability of gentamicin sulfate and tobramycin sulfate in extemporaneously prepared ophthalmic solutions at 8 degrees C. Am J Hosp Pharm. 1991;48(3):507–9.

    PubMed  CAS  Google Scholar 

  • McElhiney LF. Compounding Guide for Ophthalmic Preparations. 1st Edition. American Pharmacists Association, Washington DC. 2013.

    Google Scholar 

  • McLellan C, Pasedis S, Dohlman CH. Testing long term stability of vancomycin ophthalmic solution. Int J Pharm Compd. 2008;12(5):456–9.

    CAS  Google Scholar 

  • Morlet N, Young S, Naidoo D, Fong T, Coroneo MT. High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study. Br J Ophthalmol. 1995;79:753–5.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Moorfields Eye Hospital NHS Foundation trust. Pharmacists Handbook. Moorfields Pharmaceuticals, 2006. Available at: http://mehhome/_uploads/documents/policy-documents/clinical-guidelines/moorfields-pharmacists-handbook-(2006).pdf.

    Google Scholar 

  • Murry T. Accreditation by the pharmacy compounding accreditation board: raising the bar for patient care. Int J Pharm Compd. 2008;12(2):174–5.

    Google Scholar 

  • Nahata MC, Allen LV. Extemporaneous drug formulations. Clin Ther. 2008;30(11):2112–9.

    Article  PubMed  Google Scholar 

  • Nentwich MM, Kollmann KHM, Meshack J, Ilako DR, Schaller UC. Microbial contamination of multi-use ophthalmic solutions in Kenya. Br J Ophthalmol. 2007;91(10):1265–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Neoh CF, Jacob J, Leung L, Li J, Stathopoulos A, Stewart K, Kong DC. Stability of extemporaneously prepared 0.5-percent caspofungin eye drops: a potential cost-savings exercise. Antimicrob Agents Chemother. 2012;56(6):3435–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Parke DW. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act. 2013. Available at http://www.prnewswire.com/news-releases/american-academy-of-ophthalmology-issues-statement-on-provisions-to-pharmaceutical-compounding-quality-and-accountability-act-209358771.html. Assessed on 3 Apr 2015.

  • Pharmaceutical Compounding Expert Committee. Pharmaceutical compounding. In: United States Pharmacopeia 34/National Formulary 29. Rockville: United States Pharmacopeial Convention; 2011.

    Google Scholar 

  • Phasukkijwatana N, Lertrit P, Liammongkolkul S, Prabhasawat P. Stability of epitheliotrophic factors in autologous serum eye drops from chronic Stevens-Johnson syndrome dry eye compared to non-autoimmune dry eye. Curr Eye Res. 2011;36(9):775–81. doi:10.3109/02713683.2011.587935.

    Article  PubMed  CAS  Google Scholar 

  • Pilatti C, del CM, Chiale TC, Spinetto M. Stability of pilocarpine ophthalmic solutions. Drug Dev Ind Pharm. 1999;25(6):801–5.

    Article  PubMed  CAS  Google Scholar 

  • Pohloudek-Fabini R, Martin E, Gallasch V. Contribution to the stability of tropicamide solutions. Pharmazie. 1982;37(3):184–7.

    PubMed  CAS  Google Scholar 

  • Rahman MQ, et al. Microbial contaminations of preservative free multiple application containers. Br J Ophthalmol. 2006;90:139–41.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Reynolds L, Closson R, editors. Extemporaneous ophthalmic preparations. Vancouver: Applied Therapeutics Inc; 1993. p. 288–90.

    Google Scholar 

  • Robert MC, Spurr-Michaud S, Frenette M, Young D, Gipson IK, Dohlman CH. Stability and in vitro toxicity of an infliximab eye drop formulation. Int J Pharm Compd. 2014;18(5):418–26.

    PubMed  CAS  Google Scholar 

  • Rogers C, Dakin HA, Wordsworth S. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration: 1 year IVAN results. Program and abstracts of the Association for Research in Vision Ophthalmology (ARVO) 2013 Annual Meeting; May 5–9, 2013; Seattle, Washington. Abstract 373.

    Google Scholar 

  • Rojanarata T, Tankul J, Woranaipinich C, Potawanich P, Plianwong S, Sakulma S, Saehuan C. Stability of fortified cefazolin ophthalmic solutions prepared in artificial tears containing surfactant-based versus oxidant-based preservatives. J Ocul Pharmacol Ther. 2010;26(5):485–90.

    Article  PubMed  CAS  Google Scholar 

  • Ruiz L, Rodriguez I, Baez R, Aldana R. Stability of an extemporaneously prepared recombinant human interferon alfa-2b eye drop formulation. Am J Health Syst Pharm. 2007;64(16):1716–9.

    Article  PubMed  CAS  Google Scholar 

  • Salvatore G, Focke Z. Bevacizumab: off label use in ophthalmology. Indian J Ophthalmol. 2007;55(6):417–20.

    Article  Google Scholar 

  • Sandle T. Sterile Ophthalmic Preparations and Contamination Control. 2014. Available at http://www.ivtnetwork.com/article/sterile-ophthalmic-preparations-and-contamination-control.

  • Sautou V. Stability of ophthalmic preparation. 2010. Available at http://www.gerpac.eu/spip.php?article69. Accessed on 2 Mar 2015.

  • Schein OD, Wasson PJ. Microbial keratitis associated with contaminated ocular medications. Am J Ophthalmol. 1988;105(4):361–5.

    Article  PubMed  CAS  Google Scholar 

  • Schein OD, et al. Microbial contamination of in-use ocular medications. Arch Ophthalmol. 1992;110:82–5.

    Article  PubMed  CAS  Google Scholar 

  • Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK. A safety review and meta-analyses of Bevacizumab and Ranibizumab: off-label versus gold standard. PLoS One. 2012;7(8), e42701. doi:10.1371/journal.pone.0042701.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Seal DV. Endophthalmitis prophylaxis – implications of the European society of cataract and refractive surgery endophthalmitis study. Eur Ophthalmol Rev. 2007;1:30–2. doi:10.17925/EOR.2007.00.01.30.

  • Sellers S, Utian WH. Pharmacy compounding primer for physicians. Curr Opin Drug. 2012;72(16):2043–50.

    Google Scholar 

  • Senthilkumari S, Lalitha P, Prajna NV, Haripriya A, Nirmal J, Gupta P, Velpandian T. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. Curr Eye Res. 2010;35(11):953–60.

    Article  PubMed  CAS  Google Scholar 

  • Shargel L. Comprehensive pharmacy review. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 1997.

    Google Scholar 

  • Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology. 1997;48(1):249–53.

    Article  PubMed  CAS  Google Scholar 

  • Spark MJ. Compounding of medicines by pharmacies: An update. Maturitas. 2014. Available at http://dx.doi.org/10.1016/j.maturitas.2014.05.00.

  • Staes C, Jacobs J, Mayer J, Allen J. Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000–12. Am J Health Syst Pharm. 2013;70(15):1301–12.

    Article  PubMed Central  PubMed  Google Scholar 

  • Stevens JD, Matheson MM. Survey of the contamination of eye drops of hospital inpatients and recommendations for the changing of current practice in eyedrop dispensing. Br J Ophthalmol. 1992;76:36–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. USFDA, Sep 2004. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070342.pdf.

  • Stokowski LA. The Compounding Controversy. Medscape. Jul 03, 2013.

    Google Scholar 

  • Sundstrom S, Ljungqvist B, Reinmuller B. Some observations on airborne particles in the critical areas of a blow-fill-seal machine. PDA J Pharm Sci Technol. 2009;63(1):71–80.

    PubMed  Google Scholar 

  • Taban M, et al. Acute endophthalmitis following cataract surgery a systematic review of the literature. Arch Ophthalmol. 2005;123:613–20.

    Article  PubMed  Google Scholar 

  • Templeton WC. Serratia keratitis transmitted by contaminated eyedroppers. Am J Ophthalmol. 1982;93(6):723–6.

    Article  PubMed  Google Scholar 

  • The Ann. Deadly Meds. 2013. Available at http://www.theannmagazine.com/2013/01/04/deadlymeds/. Accessed 02 Mar 2015.

  • Tortora GJ, Grabowski SR, editors. Principles of anatomy and physiology. 10th ed. New York: Wiley; 2002. p. 866–73.

    Google Scholar 

  • Trissel LA. Trissel’s stability of compounded formulations. 4th ed. Washington, DC: American Pharmacists Association; 2009. p. 26–7.

    Google Scholar 

  • Tsilou ET, Thompson D, Linblad AS, et al. A multicentre randomized double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br J Ophthalmol. 2003;87(1):8–31.

    Article  Google Scholar 

  • Uhart M, Pirot F, Boillon A, Senaux E, Tall L, Diouf E, Burillon C, Padois K, Falson F, Leboucher G, Pivot C. Assessment of sodium hyaluronate gel as vehicle for intracameral delivery of cefuroxime in endophthalmitis prophylaxis. Int J Pharm. 2010;398(1–2):14–20. Available at doi:10.1016/j.ijpharm.2010.07.009. Epub 2010 Jul 15.

    Article  PubMed  CAS  Google Scholar 

  • United states pharmacopoeia. General Chapter <1231> Water for pharmaceutical purposes, USP 29–NF24. Rockville, MD: United States Pharmacopeia Convention; 2006.

    Google Scholar 

  • United States Pharmacopeia. General chapter <1116> microbiological control and monitoring of aseptic processing environments, USP 35–NF 30. Bethesda: United States Pharmacopeia; 2012.

    Google Scholar 

  • US Department of Health and Human Services. US FDA. FDA alerts health care professionals of infection risk from repackaged avastin intravitreal injections. 2011. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm270296.htm.

  • USP <797> The United States Pharmacopoeia 27 National Formulary 22 (USP‐NF). Chapter 797: Pharmaceutical Compounding. 2004. USP Convention. 2008:1–61.

    Google Scholar 

  • USP <797> United States Pharmacopeia. General chapter <1116> microbiological control and monitoring of aseptic processing environments, USP 35–NF 30. Bethesda: United States Pharmacopeia; 2012.

    Google Scholar 

  • Velpandian T, Saluja V, Ravi A, Kumari SS, Mathur R, Ranjan N, Ghose S. Evaluation of the stability of extemporaneously prepared ophthalmic formulation of mitomycin C. J Ocul Pharmacol Ther. 2005;21(3):217–22. doi:10.1089/jop.2005.21.217.

    Article  PubMed  CAS  Google Scholar 

  • Velpandian T, Sharma C, Garg SP, Mandal S, Ghose S. Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries. Indian J Ophthalmol. 2007;55:488–90. (PMCID: PMC2635973) (PubMed: 17951922).

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Williams RD, Thompson J, Epley DK, Liebermann JM, Tan D. Letter on compounding pharmacies. American Association for Pediatric Ophthalmology and Strabismus. 2013. Available at http://www.aapos.org/news/show/109. Accessed 28 May 2013.

  • Wong D, Kyle G. Some ethical considerations for the “off-label” use of drugs such as Avastin. Avastin: ethical considerations. Commentaries. Br J Ophthalmol. 2006;90:1218–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Wroblewski KJ, Pasternak JF, Bower KS. Infectious keratitis after photorefractive keratectomy in the United States army and navy. Ophthalmology. 2006;113(4):520–5.

    Article  PubMed  Google Scholar 

  • Wycoff CC, et al. Nosocomial acute-onset postoperative endophthalmitis at a University Teaching Hospital (2002–2009). Am J Ophthalmol. 2010;150:392–8.

    Article  Google Scholar 

  • Wynkoop K. Compounded products: use, regulation, and risk. OMIC digest. Fall 2012.

    Google Scholar 

  • Yuen JR, Fiscella RG, Gaynes BI. Ophthalmic agents and managed care. J Manag Care Pharm. 2002;8(3):217–23.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ocular Pharmacology and Pharmacy, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India

    Thirumurthy Velpandian BPharm, MS(Pharmacol), PhD & Ujjalkumar S. Das MPharm

Authors
  1. Thirumurthy Velpandian BPharm, MS(Pharmacol), PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ujjalkumar S. Das MPharm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thirumurthy Velpandian BPharm, MS(Pharmacol), PhD .

Editor information

Editors and Affiliations

  1. Ocular Pharmacology and Pharmacy, Dr. RP Centre for Ophthalmic Sciences, New Delhi, India

    Thirumurthy Velpandian

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Velpandian, T., Das, U.S. (2016). Extemporaneously Used Drug Formulations for Ocular Emergencies. In: Velpandian, T. (eds) Pharmacology of Ocular Therapeutics. Adis, Cham. https://doi.org/10.1007/978-3-319-25498-2_15

Download citation

Publish with us

Policies and ethics

Search

Navigation